Steve M. Sabus - 05 Dec 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Reporting relationship: Chief Commercial Officer
Issuer ticker: SNDX
Reported as of: 05 Dec 2022
Net transaction value: +$5,596,800
SEC form: 4
Accepted by SEC: 05 Dec 2022, 15:41:39 UTC
Prior SEC filing: 17 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael A. Metzger, Attorney-in-Fact

Key filing fact

Steve M. Sabus filed Form 4 for Syndax Pharmaceuticals Inc (SNDX) on 05 Dec 2022.

Key facts

This page summarizes Steve M. Sabus's Form 4 filing for Syndax Pharmaceuticals Inc (SNDX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Dec 2022, 15:41.

Change

Previous filing in this sequence was filed on 17 Aug 2022.
Current net transaction value: +$5,596,800.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SNDX transaction Derivative

Stock Options (Right to buy)

Award

Transaction value: $5,596,800
Shares: +220,000
Change %
Price: $25.44
Shares after: 220,000
Date: 05 Dec 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 220,000
Exercise price: $25.44
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Twenty five percent (25%) of the total number of shares underlying the option shall vest on December 5, 2023, and one-thirty-sixth (1/36th) of the remaining shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates.